DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jones, Rob, Sheehan, Bart, Phillips, Patrick, Juszczak, Ed, Adams, Jessica, Baldwin, Ashley, Ballard, Clive, Banerjee, Sube, Barber, Bob, Bentham, Peter, Brown, Richard, Burns, Alistair, Dening, Tom, Findlay, David, Gray, Richard, Griffin, Mary, Holmes, Clive, Hughes, Alan, Jacoby, Robin, Johnson, Tony, Jones, Roy, Knapp, Martin, Lindesay, James, McKeith, Ian, McShane, Rupert, Macharouthu, Ajay, O'Brien, John, Onions, Caroline, Passmore, Peter, Raftery, James, Ritchie, Craig, Howard, Rob
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2009
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2723100/
https://ncbi.nlm.nih.gov/pubmed/19630974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-10-57
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires